Variable

BMI

P-value^†

BSA

P-value^†

≤30 kg/m²

>30 kg/m²

≤1.85 m²

>1.85 m²

N = 31 (%)

N = 84 (%)

N (%)

N (%)

Menopausel status

Premenopausal

18 (58.1%)

51 (60.7%)

0.799

26 (54.2%)

43 (64.2%)

0.284

Postmenopausal

13 (41.9%)

33 (39.3%)

22 (45.8%)

24 (35.8%)

T staging

T1

5 (16.1%)

19 (22.6%)

0.857^‡

12 (25%)

12 (17.9%)

0.236^‡

T2

13 (41.9%)

33 (39.3%)

19 (39.6%)

27 (40.3%)

T3

13 (41.9%)

26 (31%)

16 (33.3%)

23 (34.3%)

T4

0 (0%)

6 (7.1%)

1 (2.1%)

5 (7.5%)

Stage T3/T4

T1/T2

18 (58.1%)

52 (61.9%)

0.708

31 (64.6%)

39 (58.2%)

0.490

T3/T4

13 (41.9%)

32 (38.1%)

17 (35.4%)

28 (41.8%)

N stage

N0

6 (19.4%)

17 (20.2%)

0.692^‡

11 (22.9%)

12 (17.9%)

0.272^‡

N1

12 (38.7%)

35 (41.7%)

13 (27.1%)

34 (50.7%)

N2

10 (32.3%)

26 (31%)

19 (39.6%)

17 (25.4%)

N3

3 (9.7%)

6 (7.1%)

5 (10.4%)

4 (6%)

Stage N2/N3

Tumor staging

N0/N1

18 (58.1%)

52 (61.9%)

0.708

24 (50%)

46 (68.7%)

0.043

N2/N3

13 (41.9%)

32 (38.1%)

24 (50%)

21 (31.3%)

Stage I

0 (0%)

6 (7.1%)

0.68^‡

1 (2.1%)

5 (7.5%)

0.741^‡

Stage II

16 (51.6%)

27 (32.1%)

22 (45.8%)

21 (31.3%)

Stage III

15 (48.4%)

51 (60.7%)

25 (52.1%)

41 (61.2%)

Tumor stage I, II/III

Stage I/II

16 (51.6%)

33 (39.3%)

0.236

23 (47.9%)

26 (38.8%)

0.330

Stage III

15 (48.4%)

51 (60.7%)

25 (52.1%)

41 (61.2%)

ER

ER−

8 (25.8%)

19 (22.6%)

0.72

11 (22.9%)

16 (23.9%)

0.904

ER+

23 (74.2%)

65 (77.4%)

37 (77.1%)

51 (76.1%)

PR

PR−

11 (35.5%)

28 (33.3%)

0.829

19 (39.6%)

20 (29.9%)

0.277

PR+

20 (64.5%)

56 (66.7%)

29 (60.4%)

47 (70.1%)

HER2

HER2−

24 (77.4%)

61 (72.6%)

0.603

33 (68.8%)

52 (77.6%)

0.286

HER2+

7 (22.6%)

23 (27.4%)

15 (31.3%)

15 (22.4%)

Molecular subtype

HR+

19 (61.3%)

50 (59.5%)

0.888^‡

26 (54.2%)

43 (64.2%)

0.448^‡

HR+/HER2+

4 (12.9%)

14 (16.7%)

9 (18.8%)

9 (13.4%)

HER2+

3 (9.7%)

9 (10.7%)

6 (12.5%)

6 (9%)

TN

5 (16.1%)

11 (13.1%)

7 (14.6%)

9 (13.4%)